Kneu Health
Kneu Health is pioneering continuous intelligence for neurological care through smartphone-based monitoring of Parkinson’s and dementia. Built on Oxford University’s decade-long longitudinal research and validated across leading health systems, the company’s FDA-cleared platform transforms daily interactions into clinical insights that enable earlier intervention and personalized care.
Backed by Oxford Science Enterprises, Cedars-Sinai, and a global syndicate of investors, Kneu operates across eight UK National Health Service (NHS) Trusts and flagship U.S. health systems.
The company’s purpose is to shape a future where people live full lives with neurological conditions, supported by systems that work in their favor.
Co-founded in 2022, by Caroline Cake, the fight was personal after seeing her mother and grandmother navigate dementia with little change in care in 30 years. Fellow co-founder Dr Kinan Muhammed saw the need to translate research into solutions that he knew could improve lives, but that were slow to reach the people who needed it. Joined by Professors Michele Hu and Masud Husain, the team turned shared frustration into a mission to deliver solutions faster.
Armed with a decade of Oxford-led research and clinical validation, Kneu unites neurologists, neuroscientists, and data scientists to bring clarity to complexity, making care more objective, immediate, and continuous for people living with these challenging conditions.
In October 2025, the JIMCO Technology Fund participated in US$ 5.6 million oversubscribed seed funding round, co-led by Oxford Science Enterprises and Cedars-Sinai. The funding will accelerate US expansion by scaling Parkinson’s deployments, expanding commercial capacity, and publishing outcome data, while also advancing dementia monitoring.
Kneu transforms everyday devices such as smartphones into powerful monitoring tools, using AI-powered insights to help clinicians act earlier and patients feel more in control. The team brings clinical insight, technical depth, and a clear focus on better neurology care.
Backed by over a decade of Oxford research, Kneu transforms smartphones into clinical-grade monitors for neurological conditions, starting with Parkinson’s and dementia. By capturing subtle changes in movement, cognition, and wellbeing, their technology provides objective insights that go beyond self-reporting. This empowers people living with neurological conditions, supports clinicians in delivering more personalized care, and helps health systems in the UK and US reduce pressures while improving outcomes.
Explore other partners
